Recce Pharmaceuticals Ltd (RCE.AX)
Recce Pharmaceuticals Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.38, up 0.00% on the session, giving a market capitalisation of $114.7M. Its beta of 0.39 implies it has historically moved less than the broad market.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Recce Pharmaceuticals Ltd is most often compared with the following Healthcare names: